Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis

Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis

Introduction The relative efficacy and safety of once-daily oral semaglutide vs. injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in subjects with type 2 diabetes (T2D) inadequately controlled on basal insulin were assessed using network meta-analysis (NMA). Methods A systematic lite...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes therapy 2021-05, Vol.12 (5), p.1325-1339
Hauptverfasser: Chubb, Barrie, Gupta, Palvi, Gupta, Jatin, Nuhoho, Solomon, Kallenbach, Klaus, Orme, Michelle
Format: Artikel
Sprache:eng
Schlagworte:
Antidiabetics
Cardiology
Comparative analysis
Diabetes
Endocrinology
GLP-1 receptor agonists
Insulin
Internal Medicine
Medicine
Medicine & Public Health
Oral medication
Original Research
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction The relative efficacy and safety of once-daily oral semaglutide vs. injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in subjects with type 2 diabetes (T2D) inadequately controlled on basal insulin were assessed using network meta-analysis (NMA). Methods A systematic literature review (SLR) was performed to identify randomised controlled trials of GLP-1 RAs in this population. Data at 26 ± 4 weeks were extracted for efficacy and safety outcomes feasible for the NMA: change from baseline in glycated haemoglobin (HbA 1c ), weight and blood pressure; HbA 1c target levels (
ISSN:1869-6953
1869-6961
DOI:10.1007/s13300-021-01034-w